Jonna K. van Vulpen , Hidde Eijkelenkamp , Guus Grimbergen , Frank J. Wessels , Sasja F. Mulder , Gert J. Meijer , Martijn P.W. Intven
{"title":"Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma","authors":"Jonna K. van Vulpen , Hidde Eijkelenkamp , Guus Grimbergen , Frank J. Wessels , Sasja F. Mulder , Gert J. Meijer , Martijn P.W. Intven","doi":"10.1016/j.phro.2024.100683","DOIUrl":null,"url":null,"abstract":"<div><div>Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"32 ","pages":"Article 100683"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650256/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physics and Imaging in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405631624001532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.
立体定向全身放射治疗（SBRT）可能是治疗肾细胞癌（RCC）胰腺少转移患者的一种非侵入性策略。我们分析了11例接受mr引导的SBRT治疗的31例胰腺少转移灶。在中位31.6个月的随访中，1年和2年的局部进展自由度分别为100%和95% （95% CI 86- 100%）。此外，1年和2年的全身治疗自由度分别为91% （95% CI 75- 100%）和82% （95% CI 62- 100%）。mr引导下的SBRT可能是一种安全有效的治疗RCC胰腺少转移的选择。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
